DAVID ALTSHULER - 07 Nov 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
07 Nov 2022
Net transactions value
-$150,507
Form type
4
Filing time
09 Nov 2022, 15:40:50 UTC
Previous filing
10 Aug 2022
Next filing
17 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $244,352 +1,303 +3.6% $187.53 37,380 07 Nov 2022 Direct
transaction VRTX Common Stock Sale $41,961 -140 -0.37% $299.72 37,240 07 Nov 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $63,202 -210 -0.56% $300.96 37,030 07 Nov 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale $57,076 -189 -0.51% $301.99 36,841 07 Nov 2022 Direct F1, F2, F5
transaction VRTX Common Stock Sale $79,138 -261 -0.71% $303.21 36,580 07 Nov 2022 Direct F1, F2, F6
transaction VRTX Common Stock Sale $85,282 -280 -0.77% $304.58 36,300 07 Nov 2022 Direct F1, F2, F7
transaction VRTX Common Stock Sale $42,755 -140 -0.39% $305.39 36,160 07 Nov 2022 Direct F1, F2, F8
transaction VRTX Common Stock Sale $25,445 -83 -0.23% $306.57 36,077 07 Nov 2022 Direct F1, F2, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1,303 -50% $0.000000 1,304 07 Nov 2022 Common Stock 1,303 $187.53 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97).
F4 Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18).
F5 Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20).
F6 Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45).
F7 Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91).
F8 Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39).
F9 Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22).
F10 The option vests in 16 quarterly installments from 2/6/2019.